Document is current
Any future updates will be listed below
-
Authors
,
Baker, Jillian M.
Shehata, Nadine
Bussel, James
Murphy, Michael F.
Greinacher, Andreas http://orcid.org/0000-0001-8343-7336
Bakchoul, Tamam
Massey, Edwin
Lieberman, Lani
Landry, Denise
Tanael, Susano
Arnold, Donald M.
Baidya, Shoma
Bertrand, Gerald http://orcid.org/0000-0003-2219-1082
Kjaer, Mette
Kaplan, Cécile
Kjeldsen-Kragh, Jens
Oepkes, Dick
Savoia, Helen
Ryan, Greg
Hume, Heather
-
Funding
Funding for this research was provided by:
Canadian Blood Services (N/A)
- License Information
-
More Information
Article History
Received: 19 October 2018
Revised: 26 February 2019
Accepted: 1 March 2019
First Online: 10 April 2019
Compliance with ethical standards
:
: MK and JK-K are two of the founders and owners of Prophylix Pharma AS, a Norwegian biotech company coordinating the EU-funded PROFNAIT Consortium which is developing a prophylaxis against fetal and neonatal alloimmune thrombocytopenia (FNAIT). DO has received research funding to a project “Towards routine HPA-screening in Pregnancy”. NS and DMA are consultants for Canadian Blood Services. J Bussel is a consultant of Baxalta, Superior Biologics and Prophylix Pharma. The remaining authors report no conflict of interest.
